Media


  • 23 Mar 2017

McGill researchers receive over $7M to fight brain diseases of aging

Link: http://publications.mcgill.ca/reporter/2017/03/mcgill-researchers-receive-over-7m-to-fight-brain-diseases-of-aging/

“The Weston Brain Institute is seriously committed to supporting ground-breaking research in neurodegeneration in Canada” “My research in inflammatory pathways underlying AD wouldn’t be possible to conduct without their incredible support and vision.”

Dr. Pedro Rosa-Neto, Director of McGill University Research Centre for Studies in Aging

 

 

  • 20 Mar 2017

Weston Brain Institute announces awardees of more than $30 million in grants to fight brain diseases of aging

Link: http://www.newswire.ca/news-releases/weston-brain-institute-announces-awardees-of-more-than-30-million-in-grants-to-fight-brain-diseases-of-aging-616600214.html

The Early Phase Clinical Trials Program (up to $1.7m) supports Phase I and IIa clinical trials. This is an innovative funding opportunity whereby applicants have optional access to clinical trials design experts to help improve their study designs. Grantees include:

  • Dr. Pedro Rosa-Neto of Douglas Hospital Research Centre: testing in a first-in-human trial the safety and efficacy of a new drug that can potentially cross the blood brain barrier and promote amyloid clearance in early Alzheimer’s disease patients.

 

 

  • 20 Feb 2017

Enigma Biomedical Group Signs Research Agreement with McGill University Research Centre for Studies in Aging

Link: http://www.businesswire.com/news/home/20170220005696/en

 

“These research projects will provide valuable insight into the status and progression of NFTs in healthy subjects, subjects with mild cognitive impairment and confirmed Alzheimer’s Disease. We appreciate the support of Enigma Biomedical Group and value our ongoing relationship.”

Dr. Pedro Rosa-Neto, Director of McGill University Research Centre for Studies in Aging

 

“The ability to visualize and quantify tau in the brain will facilitate therapeutic research in the field of Alzheimer’s disease.”

Dr. Serge Gauthier, Director of the AD & Related Disorders Research Unit of the McGill University Research Center for Studies in Aging

 

 

  • 09 Feb 2017

Do Astrocytes Blur the PET Signal for ‘Neuronal’ Activity?

Link: http://www.alzforum.org/news/research-news/do-astrocytes-blur-pet-signal-neuronal-activity

“This has implications for understanding what FDG PET means as an outcome measure in clinical trials. It may reflect intervention effects on astrocytes as well as neurons,”

Dr. Pedro Rosa-Neto

 

 

  • 31 Jan 2017

Les astrocytes nous éclairent sur le fonctionnement du cerveau

Link https://www.unil.ch/central/en/home/news.html?showActu=1485856972121&showFrom=1